Co-crystals and salts of CCR3-inhibitors

Patent metadata

Field	Value
Publication number	US-9233950-B2
Application number	US-201414572889-A
Country	US
Kind code	B2
Filing date	Dec 17, 2014
Priority date	Oct 7, 2010
Publication date	Jan 12, 2016
Grant date	Jan 12, 2016

Abstract

This invention relates to co-crystals and salts of CCR3 inhibitors of formula 1,

pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of diseases related with the CCR3-receptor.

First claim

What we claim:

1. A crystalline salt of formula 1a

2. A crystalline salt of formula 1b

3. The crystalline salt according to claim 1 characterized in that the four highest X-ray powder diffraction peaks occur at 3.72, 13.60, 16.89 and 19.34 degrees 2θ (±0.05 degrees 2θ) when measured using CuKα radiation.

4. The crystalline salt according to claim 2 characterized in that the four highest X-ray powder diffraction peaks occur at 16.02, 16.86, 19.45 and 19.71 degrees 2θ (±0.05 degrees 2θ) when measured using CuKα radiation.

Assignees

• Boehringer Ingelheim Int

Inventors

• Frank Markus
• Haeberle Hans
• Henry Manuel
• Pachur Thorsten
• Santagostino Marco
• Stertz Uwe
• Trebing Thomas
• Werthmann Ulrike

Classifications

• A61P37/08

  Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14) · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P27/02

  Ophthalmic agents · CPC title

• A61P31/12

  Antivirals · CPC title